Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Group 1 - The company, Haofan Bio (301393), stated that its operations are normal and its core business is steadily advancing [1] - The company is continuously improving operational efficiency and core competitiveness [1] - The company aims to reward investors with good operating performance [1] Group 2 - The stock price is influenced by multiple factors in the secondary market, and investors are advised to view it rationally [1]

Core Viewpoint - Haofan Bio emphasizes the importance of market value management, focusing on steady operations, continuous innovation, and standardized governance to create long-term value for shareholders [2] Group 1: Company Actions - The company has implemented several measures since its listing, including cash dividends, share buybacks, equity incentives, and executive stock purchases to boost market confidence [2] - Haofan Bio is committed to enhancing the quality of information disclosure and actively improving investor relations management to increase transparency and investor understanding [2] Group 2: Future Commitment - The company will continue to strengthen its market value management efforts and will fulfill information disclosure obligations regarding significant matters in designated media [2]

Group 1 - The report highlights the recent performance of various industries, with notable gains in sectors such as non-ferrous metals, electronics, and power equipment, while retail and real estate sectors faced declines [1][1][1] - The central economic work conference emphasized the importance of technological breakthroughs and supply-demand optimization, indicating a shift towards quality improvement in economic growth [11][12][19] - The commercial aerospace sector is experiencing significant growth, with the establishment of a dedicated regulatory body and a notable increase in the commercial aerospace index, which has risen by 46.52% since April 7 [47][48] Group 2 - The report indicates a seasonal recovery in social financing, with November seeing an increase of 24,885 billion yuan, driven primarily by government bond issuance [4][7] - The credit environment is showing signs of marginal improvement, particularly in corporate loans, which increased by 6,100 billion yuan in November, reflecting a recovery in demand [5][6] - The report notes that the retail sector is undergoing a transformation, with a focus on quality, as highlighted by the Ministry of Commerce's emphasis on retail quality upgrades [1][1][1] Group 3 - The report discusses the rising interest in inquiry transfers, which have seen a significant increase in both project numbers and transfer scale, indicating a growing trend in the market [51][52] - The technology sector is expected to remain a key focus, with upcoming events such as the Volcano Engine FORCE conference anticipated to showcase advancements in AI and cloud services [56]

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

Group 1 - The company announced the convening of a staff representative meeting on December 10, 2025 [2] - Mr. Lv Minjie has been elected as the employee representative director for the fourth board of directors, with a term starting from the date of election until the end of the fourth board's term [2]

Core Viewpoint - Haofan Bio is progressing with the construction of its production base in Huai'an, planning to build 10 production workshops in total, with an initial phase of 5 workshops set for trial production by 2026 [1] Group 1 - The company plans to construct production lines in phases to ensure safe, rapid, and orderly capacity construction [1] - The project is currently advancing according to the established plan, with management providing estimates based on current construction progress and site conditions [1] - The company will disclose important updates regarding capacity construction in regular reports and temporary announcements to ensure fair information disclosure [1]

上海市广发律师事务所 关于苏州昊帆生物股份有限公司 2025 年第一次临时股东大会的法律意见书 致：苏州昊帆生物股份有限公司 苏州昊帆生物股份有限公司（以下简称"公司"）2025 年第一次临时股东 大会于 2025 年 12 月 10 日在江苏省苏州高新区长亭路 1 号公司会议室召开。上 海市广发律师事务所经公司聘请，委派何晓恬律师、顾艳律师出席本次会议，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会 规则》（以下简称"《股东会规则》"）等法律法规、其他规范性文件以及《苏 州昊帆生物股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次 股东大会的召集和召开程序、召集人及出席会议人员的资格、会议议案、表决方 式和表决程序、表决结果和会议决议等出具本法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 公司已向本所保证和承诺，公司向本所律师所提供的文件和所作的陈述和说 明是完整的、真实的和有效的，有关原件及其上面的签字和印章是真实的，且一 切足以影响本法律意见书的事实和文件均已向本所披露， ...

证券代码：301393 证券简称：昊帆生物 公告编号：2025-063 2025 年 12 月 10 日 苏州昊帆生物股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司（以下简称"公司"）于 2025 年 12 月 10 日召 开 2025 年第一次临时股东大会，审议通过了《关于修订<公司章程>的议案》。 根据修订后的《公司章程》，公司设职工代表董事 1 名，由公司职工代表大会选 举产生。 公司于 2025 年 12 月 10 日召开职工代表大会，经与会职工代表表决，选举 吕敏杰先生（简历详见附件）为公司第四届董事会职工代表董事，任期自本次职 工代表大会选举通过之日起至第四届董事会任期届满之日止。吕敏杰先生原为公 司第四届董事会非职工代表董事，本次选举完成后变更为第四届董事会职工代表 董事，公司第四届董事会成员及专门委员会成员构成不变。 吕敏杰先生符合《公司法》《公司章程》规定的有关职工代表董事任职资格 和条件。吕敏杰先生当选公司职工代表董事后，公司第四届董事会中兼任公司高 级管理人员以及由职工代 ...

证券代码：301393 证券简称：昊帆生物 公告编号：2025-062 苏州昊帆生物股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议时间： （1）现场会议召开日期：2025 年 12 月 10 日 14:30 参加本次股东大会表决的股东和股东代表（包括委托代理人）58 名，代表 股份 69,175,221 股，占公司有表决权股份总数（扣除回购专户 818,148 股）的 1 （2）互联网投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为: 2025 年 12 月 10 日 9:15—9:25，9:30—11:30，13:00—15:00; ②通过深圳证券交易所互联网投票系统进行网络投票的具体时间为: 2025 年 12 月 10 日 9:15—15:00。 2、会议地点：江苏省苏州高新区长亭路 1 号，昊帆生物会议室 3、会议召开方式：现场表决与网络投票 ...